Stereotaxis, Inc.

298 articles about Stereotaxis, Inc.

• Stereotaxis Reports 2023 First Quarter Financial Results

  5/9/2023

  Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today reported financial results for the first quarter ended March 31, 2023.

• Stereotaxis to Report First Quarter 2023 Financial Results on May 9, 2023

  4/18/2023

  Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it will release financial results for its 2023 first quarter on Tuesday, May 9, 2023 before the open of the U.S. financial markets.

• Over 1,000 Cardiac Patients Treated with Genesis Robotic System

  4/13/2023

  Stereotaxis, a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, announced that over 1,000 cardiac arrhythmia patients have been treated using the Genesis Robotic Magnetic Navigation system.

• Broward Health Medical Center the First Hospital in Florida Using Advanced Genesis Robotic Technology to Treat Heart Rhythm Disorders

  3/20/2023

  Stereotaxis announced the grand opening of a new robotic electrophysiology program at Broward Health Medical Center in Fort Lauderdale, Florida.

• Stereotaxis Reports 2022 Full Year Financial Results

  3/3/2023

  Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today reported financial results for the fourth quarter and full year ended December 31, 2022.

• Stereotaxis to Present at Cowen 43rd Annual Health Care Conference

  2/21/2023

  Stereotaxis, a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, announced that David Fischel, Chairman and CEO, will participate in the Cowen 43rd Annual Health Care Conference.

• Stereotaxis to Report Fourth Quarter and Full Year 2022 Financial Results on March 3, 2023

  2/2/2023

  Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it will release financial results for its 2022 fourth quarter and full year ended December 31, 2022 on Friday, March 3, 2023 before the open of the U.S. financial markets.

• Corewell Health Grows Robotic Program to Treat Heart Rhythm Disorders with Adoption of Stereotaxis’ Genesis System

  12/20/2022

  Stereotaxis announced the successful treatment of patients using the latest Genesis Robotic Magnetic Navigation system by physicians of the nationally recognized Fred & Lena Meijer Heart Center, part of Corewell Health in Grand Rapids, Michigan.

• Stereotaxis to Participate in Piper Sandler 34th Annual Healthcare Conference

  11/28/2022

  Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that David Fischel, Chairman and CEO, will participate in the Piper Sandler 34th Annual Healthcare Conference.

• Stereotaxis Reports 2022 Third Quarter Financial Results

  11/10/2022

  Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today reported financial results for the third quarter ended September 30, 2022.

• Stereotaxis to Report Third Quarter Financial Results on November 10, 2022

  10/20/2022

  Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it will release financial results for its 2022 third quarter on Thursday, November 10, 2022 before the open of the U.S. financial markets.

• Stereotaxis Receives St. Louis Mayor’s Innovation Award for 2022

  10/3/2022

  Stereotaxis, a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, announced it was awarded the 2022 Innovation Award from the Office of the Mayor of St. Louis, Tishaura O. Jones.

• International Meeting of the Society for Cardiac Robotic Navigation to Showcase Stereotaxis Technology and Its Clinical Value

  9/29/2022

  Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced its attendance at the Sixth Annual International Meeting of the Society for Cardiac Robotic Navigation (SCRN) in Budapest from September 29-30.

• Overland Park Regional Medical Center Extends Leadership in Robotic Treatment of Heart Rhythm Disorders with Plans for Second Stereotaxis System

  9/13/2022

  Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that Overland Park Regional Medical Center (OPRMC) is establishing its second robotic program for the treatment of heart rhythm disorders.

• Stereotaxis Reports 2022 Second Quarter Financial Results

  8/9/2022

  Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today reported financial results for the second quarter ended June 30, 2022.

• Stereotaxis to Report Second Quarter Financial Results on August 9, 2022

  7/19/2022

  Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it will release financial results for its 2022 second quarter on Tuesday, August 9, 2022 before the open of the U.S. financial markets.

• Stereotaxis Announces CE Mark Submission for Robotically Navigated MAGiC Ablation Catheter

  7/11/2022

  Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced the CE Mark submission for its MAGiC™ catheter.

• Journal of Atrial Fibrillation & Electrophysiology Publishes Special Issue Dedicated to Robotics in EP16 Peer-Reviewed Publications Highlight Clinical Value of Robotic Magnetic Navigation for Heart Rhythm Disorders

  6/6/2022

  Stereotaxis, the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, announces the publication of a special issue of the Journal of Atrial Fibrillation & Electrophysiology focused on the use of Robotic Magnetic Navigation for the treatment of cardiac arrhythmias.

• Stereotaxis Reports 2022 First Quarter Financial Results

  5/10/2022

  Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today reported financial results for the first quarter ended March 31, 2022.

• National Institute of Cardiology Becomes First Hospital in Poland to Establish Advanced Robotic Program to Treat Heart Rhythm Disorders

  3/24/2022

  Stereotaxis announces that Poland’s National Institute of Cardiology, the leading clinical center of cardiology and cardiac surgery in Warsaw, has established the first robotic electrophysiology program in the country with Stereotaxis’ Genesis Robotic Magnetic Navigation system.